Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
Drug Metabolism and Disposition · 2023
DOI: 10.1124/dmd.122.001096 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2023. Verfasst von Shuguang Ma und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Metabolism and Pharmacokinetics (S.M., S.C., W.Z., J.P., X.D., B.D., L.S.) and Department of Clinical Pharmacology (S.S., J.Y.H., …. Hauptthemen laut MEDLINE: Phosphatidylinositol 3-Kinases, Body Fluids. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Drug Metabolism and Pharmacokinetics (S.M., S.C., W.Z., J.P., X.D., B.D., L.S.) and Department of Clinical Pharmacology (S.S., J.Y.H., J.W.), Genentech, Inc., South San Francisco, California; and XenoBioti…
Zitieren
APA
Ma, S., Cho, S., Sahasranaman, S., Zhao, W., Pang, J., Ding, X., Dean, B., Wang, B., Hsu, J. Y., Ware, J., & Salphati, L. (2023). Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans. Drug Metabolism and Disposition. https://doi.org/10.1124/dmd.122.001096
Vancouver
Ma S, Cho S, Sahasranaman S, Zhao W, Pang J, Ding X, et al. Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans. Drug Metabolism and Disposition. 2023. doi:10.1124/dmd.122.001096
BibTeX
@article{Ma2023,
author = {Ma, Shuguang and Cho, Sungjoon and Sahasranaman, Srikumar and Zhao, Weiping and Pang, Jodie and Ding, Xiao and Dean, Brian and Wang, Bin and Hsu, Jerry Y and Ware, Joseph and Salphati, Laurent},
title = {Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans},
journal = {Drug Metabolism and Disposition},
year = {2023},
doi = {10.1124/dmd.122.001096}
}
EUVIMED